IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
David Robert Spigel, Filippo de Marinis, Giuseppe Giaccone et al. · Annals of Oncology · 2019
Cited by 146 works. doi:10.1093/annonc/mdz293
Authors
- David Robert Spigel
- Filippo de Marinis
- Giuseppe Giaccone
- Niels Reinmuth
- Alain Vergnenégre
- C.H. Barrios
- Masahiro Morise
- Enriqueta Felip
- Zoran Gojko Andric
- Sarayut Lucien Geater
- Mustafa Özgüroğlu
- Simonetta Mocci
- Mark L. McCleland
- Ida Berglin Enquist
- Kimberly Mayumi Komatsubara
- Yu Deng
- Hiroshi Kuriki
- Xiaohui Wen
- Jacek Jassem
- Roy S. Herbst